Keywords : Insulin, Drug, Insulin Glargine, Insulin Aspart, Insulin Detemir
The basal insulins are the most successful insulin class, with other insulin classes demonstrating high substitution or low and declining sales. Current basal insulins offer good safety and emerging therapies are not expected to improve efficacy significantly. However, the launch of two late-stage pipeline products Degludec and DegludecPlus in 2012–13 will alter industry dynamics....
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
The basal insulins are the most successful insulin class, with other insulin classes demonstrating high substitution or low and declining sales. Current basal insulins offer good safety and emerging therapies are not expected to improve efficacy significantly. However, the launch of two late-stage pipeline products Degludec and DegludecPlus in 2012–13 will alter industry dynamics.Understand Datamonitor’s independent appraisal of industry ed insulin brands and key pipeline agents indicated for treating type 1 and type 2 diabetes.Illustrate how pipeline and industry ed insulins compare to one another in terms of clinical and commercial attributes.Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.Understand how industry ed insulin brands are positioned in the diabetes treatment algorithm and how they are perceived by prescribers.Determine to what extent future insulin therapies satisfy the main clinical unmet needs in the treatment of type 1 and type 2 diabetes.With strong industry ing and sales resources committed by Novo Nordisk, late-stage basal insulin Degludec (insulin degludec) will offer strong competition to class leader Lantus (insulin glargine; Sanofi) and largely cannibalize predecessor Levemir (insulin detemir; Novo Nordisk).Key patents for blockbuster Lantus will expire from 2014–15. However, the threat of biosimilar insulin is expected to have less impact than typical small molecule generic drugs, as physicians are expected to be reluctant to introduce potential additional variability into patients’ insulin treatment regimens.Novo Nordisk, Sanofi, and Eli Lilly are also the only industry players with promising insulin products in late stage development. Alternative insulin delivery mechanisms under development, such as MannKind’s Afrezza (inhaled insulin), are not expected to make it to industry in the near term.What is the gold-standard basal insulin for diabetes?How are industry ed brands positioned in the insulin antidiabetics treatment algorithm?Which are the most likely insulin antidiabetics to emerge from the pipeline and how will they impact the way diabetes is managed?What are the comparative strengths and weaknesses of the key insulin antidiabetics and pipeline insulin candidates?
Drug And Medication Industry
OVERVIEW•Catalyst
•Summary
EXECUTIVE SUMMARY•Strategic scoping and focus
• Datamonitor key findings
•Related reports
•Published diabetes reports
PRODUCT OVERVIEW•Insulin use in type 1 and type 2 diabetes
•Insulin coverage in this report
MARKETED PRODUCT PROFILES•Basal insulin class overview
•Lantus (insulin glargine; Sanofi) - Drug presentation
- Drug pipeline analysis
- SWOT analysis
- Portfolio
- Physician perception of Lantus
- Clinical and commercial attractiveness
•Levemir (insulin detemir; Novo Nordisk) - Drug presentation
- Drug pipeline analysis
- SWOT analysis
- Portfolio
- Physician perception of Levemir
- Clinical and commercial attractiveness
•Other industry ed insulin antidiabetics - Fast-acting insulins
- Premixed insulins
PIPELINE PRODUCT PROFILES•Degludec (insulin degludec; Novo Nordisk) - Drug presentation
- Drug pipeline analysis
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness
•DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) - Drug presentation
- Drug pipeline analysis
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness
•Other insulin antidiabetics in development - LY2605541 (Eli Lilly/Boehringer Ingelheim)
- Improved basal insulin formulations
- Non-injected insulin formulations
BIBLIOGRAPHY•Journal papers and presentations
•Press releases
•Websites
•Datamonitor reports
APPENDIX•Exchange rates
•Datamonitor drug assessment scorecard
•Contributing experts
•Report methodology
TABLES•Table: Key industry ed and pipeline insulin products for type 1 and type 2 diabetes, 2012
•Table: Key industry ed basal insulins by onset and duration of action, 2012
•Table: Lantus (insulin glargine; Sanofi) – drug presentation, 2012
•Table: Overview of pivotal trial data for Lantus (insulin glargine; Sanofi) in diabetes, 2012
•Table: Datamonitor drug assessment summary of Lantus (insulin glargine; Sanofi) for diabetes, 2012
•Table: Levemir (insulin detemir; Novo Nordisk) – drug presentation, 2012
•Table: Overview of pivotal trial data for Levemir (insulin detemir; Novo Nordisk) in diabetes, 2012
•Table: Datamonitor drug ass essment summary of Levemir (insulin detemir; Novo Nordisk) for diabetes, 2012
•Table: Degludec (insulin degludec; Novo Nordisk) – drug presentation, 2012
•Table: Overview of pivotal published trial data for Degludec (insulin degludec; Novo Nordisk) in diabetes, 2012
•Table: Degludec (insulin degludec; Novo Nordisk) – completed and ongoing Phase III trials, 2010–12
•Table: Ability of Degludec (insulin degludec; Novo Nordisk) vs basal insulin class comparator Lantus (insulin glargine; Sanofi) to address unmet needs in diabetes, 2012
•Table: Datamonitor drug assessment summary of Degludec (insulin degludec; Novo Nordisk) for diabetes, 2012
•Table: DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) – drug presentation, 2012
•Table: Overview of pivotal published trial data for DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) in diabetes, 2012
•Table: DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) – completed and ongoing Phase III trials, 2010–12
•Table: Ability of DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) vs basal insulin class comparator Lantus (insulin glargine; Sanofi) to address unmet needs in diabetes
•Table: Datamonitor drug assessment summary of DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) for diabetes, 2012
•Table: Exchange rates to USD, annual average for 2011
•Table: Datamonitor’s drug assessment parameters for key late-stage insulin antidiabetics, 2012
FIGURES•Figure: Datamonitor’s drug assessment summary for insulin antidiabetics, 2012
•Figure: Lantus brand franchise (insulin glargine; Sanofi): SWOT analysis, 2012
•Figure: Criteria for choosing a basal insulin in the seven major industries, 2011
•Figure: Datamonitor drug assessment summary of Lantus (insulin glargine; Sanofi) for diabetes, 2012
•Figure: Levemir brand franchise (insulin detemir; Novo Nordisk) SWOT analysis in diabetes, 2012
•Figure: Datamonitor drug assessment summary of Levemir (insulin detemir; Novo Nordisk) for diabetes, 2012
•Figure: Degludec (insulin degludec, Novo Nordisk) – SWOT analysis, 2012
•Figure: Datamonitor’s drug assessment summary for Degludec (insulin degludec; Novo Nordisk), 2012
•Figure: DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) – SWOT analysis, 2012
•Figure: Datamonitor’s competitive positioning analysis of DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk), 2010
Companies mentioned
Eli Lilly and Firms, First Aviation Services Inc., Hutchison 3G UK Limited, International Game Technology, KI, MannKind Corporation
